594 related articles for article (PubMed ID: 18309481)
1. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
4. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
[TBL] [Abstract][Full Text] [Related]
5. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
6. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
7. The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.
Loudini N; Glaudemans AWJM; Jutte PC; Yakar D; Kwee TC
Skeletal Radiol; 2020 Sep; 49(9):1387-1395. PubMed ID: 32253470
[TBL] [Abstract][Full Text] [Related]
8. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
[TBL] [Abstract][Full Text] [Related]
9. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
11. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
13. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnostic value of
He X; Zhao L; Guo X; Zhao L; Wu J; Huang J; Sun L; Xie C; Chen H
Cancer Manag Res; 2018; 10():2105-2115. PubMed ID: 30050321
[TBL] [Abstract][Full Text] [Related]
15. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
16. Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase.
Kato K; Aoki J; Endo K
Ann Nucl Med; 2003 Feb; 17(1):41-6. PubMed ID: 12691129
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
[TBL] [Abstract][Full Text] [Related]
19. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
20. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
